Literature DB >> 27509127

Assessment of Minimal Residual Disease in Standard-Risk AML.

Megan Othus1, Elihu Estey2, Robert P Gale3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27509127     DOI： 10.1056/NEJMc1603847

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study.

Authors:  Andreas K Øvlisen; Anders Oest; Mette D Bendtsen; John Bæch; Preben Johansen; Line S Lynggaard; Ingolf Mølle; Thomas B Mortensen; Duruta Weber; Gideon Ertner; Claudia Schöllkopf; Jesper Q Thomassen; Ove Juul Nielsen; Lene Sofie Granfeldt Østgård; Martin Bøgsted; Karen Dybkær; Hans E Johnsen; Marianne T Severinsen
Journal:  Blood Adv       Date:  2018-03-13

2.  CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.

Authors:  Yongliang Liu; Guiqin Wang; Jiasi Zhang; Xue Chen; Huailong Xu; Gang Heng; Jun Chen; Yongchun Zhao; Jiatao Li; Yuanli Ni; Yingzi Zhang; Juanjuan Shan; Cheng Qian
Journal:  Stem Cell Res Ther       Date:  2021-01-25       Impact factor: 6.832
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.